Medivation, Inc.: Clinical Trials

13 trials sponsored by Medivation, Inc., newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

6 terminated, 5 completed, 1 unknown, 1 withdrawn. 13 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	13	Terminated 6, Completed 5, Unknown 1, Withdrawn 1

Follow Medivation, Inc.: new trials by email

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer Enzalutamide, Placebo, Paclitaxel - Breast Cancer	Phase 3	Withdrawn	Pfizer		2016-09-01	2018-10-22
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer enzalutamide, abiraterone, prednisone - Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer	Phase 3	Unknown	Alliance for Clinical Trials in Oncology	1311	2014-01-22	2023-09-28
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) talazoparib, Physician's-Choice - Breast Neoplasms, BRCA 1 Gene Mutation	Phase 3	Completed	Pfizer	431	2013-10-14	2022-01-20
An Extension of the CONCERT Protocol (DIM18) Dimebon - Alzheimer's Disease	Phase 3	Terminated	Medivation, Inc.	672	2010-04-01	2016-09-27
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease Dimebon tablet for oral administration - Alzheimer's Disease	Phase 3	Terminated	Pfizer	5	2010-04-01	2012-10-02
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease Dimebon (latrepirdine) - Huntington Disease	Phase 3	Terminated	Medivation, Inc.	362	2010-02-01	2016-10-12
A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease Dimebon (latrepirdine), Placebo - Moderate to Severe Alzheimer	Phase 3	Terminated	Medivation, Inc.	89	2009-10-01	2016-09-27
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease Dimebon - Alzheimer's Disease	Phase 3	Terminated	Pfizer	649	2009-09-01	2012-11-14
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease Dimebon 20 mg po TID, Placebo po TID - Alzheimer Disease	Phase 3	Terminated	Pfizer	86	2009-09-01	2012-10-02
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease Dimebon, Placebo - Huntington Disease	Phase 3	Completed	Medivation, Inc.	403	2009-07-01	2016-10-12
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil Dimebon, Placebo comparator - Alzheimer's Disease	Phase 3	Completed	Medivation, Inc.	1003	2009-03-01	2016-09-27
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease Dimebon, Placebo - Alzheimer's Disease	Phase 3	Completed	Pfizer	742	2009-02-01	2018-12-06
A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease Dimebon, Placebo - Alzheimer's Disease	Phase 3	Completed	Medivation, Inc.	598	2008-05-01	2016-09-27

Conditions studied

Interventions

Countries

Top investigators

Results publications

NIH funding